The combination of atezolizumab plus bevacizumab could become a standard first-line treatment for patients with metastatic nonsquamous NSCLC with high tumour mutation burden (TMB), reports a study published in  JAMA Oncology .

Among the 38 adults in the single-arm, open-label TELMA trial, median PFS with the combination was 13 months, and OS at 12 months was 72%.

The combination was "associated with...